NCT07303556Active, not recruiting
Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs
Improving the Diagnosis and Treatment of Cardiovascular Diseases in Kazakhstan by Introducing Correction of Metabolism With Glucagon-like Peptide 1 (GLP-1) Drugs
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
This clinical study aims to improve the diagnosis and treatment of cardiovascular diseases in Kazakhstan by Implementing Metabolic Correction with Glucagon-Like Peptide-1 (GLP-1). These medicines are called incretin-based therapies and include GLP-1 receptor agonists and a newer dual therapy that targets both GIP and GLP-1 receptors. Such medications have already shown benefits in lowering blood sugar, reducing body weight, improving blood pressure, and lowering the risk of serious heart complications. Cardiovascular diseases and diabetes are among the most common health problems in Kazakhstan. Many patients remain undiagnosed or receive treatment only after their condition becomes severe. This study seeks to address these challenges by testing how well dual incretin therapy works in improving heart health, blood sugar control, and overall metabolic status in adults who have both chronic heart failure and type 2 diabetes. Participants in the study will receive a detailed health evaluation at the beginning, including heart tests, blood work, and genomic profiling. Genomic testing will help researchers understand whether certain genetic features affect how patients respond to this therapy. After the initial assessment, participants will start treatment with a GIP/GLP-1 receptor agonist and will be monitored every few months for a total of 40 weeks. During these visits, their heart function, blood sugar levels, weight, and other health indicators will be checked to ensure both safety and effectiveness. The main hypothesis of the study is that dual incretin therapy will improve heart function, reduce cardiometabolic risks, and show measurable benefits in patients with both chronic heart failure and type 2 diabetes. The study also assumes that a person's genetic profile may influence how well they respond to treatment. By the end of the project, researchers hope to better understand how these medications work in the Kazakhstani population and to use these findings to support more personalized, effective, and modern approaches to treating cardiovascular diseases.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 30 Jul 2025
- Start date
- 18 Dec 2024
- Primary completion date
- 1 Jul 2025
- Lead sponsor
- Nazarbayev University
- NCT number
- NCT07303556
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 18 Dec 2024 to the primary completion date, 1 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any other antidiabetic medications (except metformin and/or sulfonylureas and basal insulin) within the past 3 months
- Use of weight loss medications, including over-the-counter drugs, within the past 3 months
Other illness
- Type 1 diabetes mellitus
- History of bariatric (weight-loss) surgery or conditions associated with delayed gastric emptying
- Acute or chronic hepatitis
- Myocardial infarction or stroke within the past 2 months
- History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorders within the past 2 years
- Healthy individuals (no cardiovascular or metabolic disease)
Lab values
- Chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73 m²
Other
- Exacerbation of chronic pancreatitis
- Acute pancreatitis
- Proliferative diabetic retinopathy, diabetic maculopathy, or non-proliferative diabetic retinopathy
- Medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) in the participant or a first-degree relative
Who the study is looking for
- Chronic heart failure with preserved ejection fraction (left ventricular ejection fraction not ≤ 45%)
- Type 2 diabetes mellitus (T2DM) with HbA1c level between ≥7.0% and ≤10.5%
- Ongoing treatment for T2DM (e.g., metformin and/or sulfonylureas, or basal insulin therapy)
- Stable body weight (±5%) for at least 3 months prior to screening
- Body mass index (BMI) ≥ 25 kg/m²
- Possible inclusion of patients with chronic pancreatitis in remission
- Aged 18 years or older, and not older than 75 years
- Both male and female participants
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PI "National Laboratory Astana", Nazarbayev University Coordinator of this site? Confirm its status | Astana | Kazakhstan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.